What are the National Comprehensive Cancer Network (NCCN) guidelines for the use of erythropoiesis-stimulating agents (ESAs) in the treatment of myelodysplastic syndrome (MDS)?

Updated: Apr 10, 2020
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

National Comprehensive Cancer Network (NCCN) guidelines recommend the use of ESAs for treatment of symptomatic anemia in patients in the R-IPSS very low risk, low risk, or intermediate risk category whose tumor lacks the 5q31 deletion and whose level of endogenous EPO is ≤500 mU/mL. [21] These patients should receive epoetin alfa, 40,000–60,000 U subcutaneously (SC), 1–3 times weekly; or darbepoetin alfa, 150–300 μg SC weekly.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!